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AbstrAct
Sepsis, the life-threatening organ dysfunction caused by 
a dysregulated host response to infection, is difficult to 
identify and to prognosticate for. In people with sepsis, 
procalcitonin (PCT) measurement aids diagnosis, enables 
therapeutic monitoring and improves prognostic accuracy. 
This study used a commercial canine PCT assay to 
measure plasma PCT concentrations in dogs with gastric 
dilatation volvulus (GDV) syndrome and in dogs with 
sepsis. It was hypothesised that dogs with GDV syndrome 
and with sepsis have greater plasma PCT concentrations 
than healthy dogs and that dogs with sepsis have greater 
PCT concentrations than dogs with GDV syndrome. Before 
analysing canine plasma samples, the ability of the assay 
to identify canine PCT, in addition to assay imprecision 
and the lower limit of detection were established. The 
assay had low imprecision with coefficients of variation 
≤4.5 per cent. The lower limit of detection was 3.4 pg/ml. 
Plasma PCT concentrations were measured in 20 dogs 
with sepsis, in 32 dogs with GDV syndrome and in 52 
healthy dogs. Median (IQR) PCT concentration in dogs with 
sepsis 78.7 pg/ml (39.1–164.7) was significantly greater 
than in healthy dogs 49.8 pg/ml (36.2–63.7) (P=0.019), 
but there were no significant differences between PCT 
concentrations in dogs with GDV syndrome and controls 
(P=0.072) or between dogs with sepsis and GDV syndrome 
(P=1.000). Dogs with sepsis have significantly increased 
plasma PCT concentrations compared with healthy dogs, 
although considerable overlap between these populations 
was identified. Future investigations should confirm this 
finding in other populations and evaluate the diagnostic 
and prognostic value of PCT in dogs with sepsis.
IntroduCtIon
Sepsis was recently redefined as the life-threat-
ening organ dysfunction caused by a dysregu-
lated host response to infection.1 Sepsis can be 
difficult to diagnose and to differentiate from 
other causes of systemic inflammation. It can 
also be challenging to provide an accurate 
prognosis for patients with sepsis. Biomarkers 
may aid clinicians with these challenges, and 
many have been investigated in human and 
canine sepsis.2 In people with sepsis, procal-
citonin (PCT) has been repeatedly demon-
strated to aid diagnosis, enable monitoring 
of response to therapy and improve prog-
nostic accuracy. In humans, increased blood 
PCT concentrations are used to differentiate 
bacterial sepsis from non-infectious systemic 
inflammatory response syndrome (SIRS).3 
In human sepsis, PCT levels correlate with 
disease severity, and predict mortality.4 5 Meas-
urement of PCT may be used to guide both 
the initiation and discontinuation of antimi-
crobial therapy.6–9 
PCT is the precursor of the hormone calci-
tonin. In health, PCT is produced by the 
parafollicular (C) cells in the thyroid gland 
and converted to calcitonin in response to 
increased plasma calcium concentrations.10 11 
In healthy people, plasma PCT concentra-
tions are typically below the level of detection 
of clinical assays (<10 pg/ml).12 PCT is regu-
lated differently during sepsis than in health.13 
In sepsis, PCT concentrations increase in 
response to an infectious stimulus and peak 
at 24 hours,3 and likely originate from mono-
cytes, neutrophils and liver, kidney, spleen 
and lung. The secretion of PCT by monocytes 
can occur in response to endotoxin and cyto-
kine stimulation,14 and is tightly regulated, 
such that it may require both pathogen recog-
nition and cell-cell interactions.15 16 PCT may 
inhibit chemotaxis,17 induce cytokines18 and 
affect vascular tone through antagonism of 
calcitonin gene-related peptide and adreno-
medullin.19 PCT also increases nitric oxide 
release and therefore may play a role in 
amplification of inflammation.20
To date, there is very little information 
regarding PCT in dogs. A gene expres-
sion study suggested that dogs with canine 
parvovirus infection had widespread expres-
sion of the Calcitonin-related Polypeptide 
Alpha (CALCA) gene in the spleen, lung and 
liver,21 likely secondary to systemic inflamma-
tion. The canine CALCA gene (UNIPROT: 
Q9MYV1) encodes the peptide hormone 
calcitonin, but can be translated into two alter-
native peptide hormones, calcitonin gene-re-
lated peptide and katacalcin by alternative 
splicing and peptide cleavage. The principal 
roles of these peptide hormones are calcium 
regulation, host defence and neurotransmis-
sion. PCT mRNA is increased in circulating 
leucocytes collected from dogs with various 
critical illnesses including sepsis and cancer,22 
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perhaps suggesting that PCT behaves as an acute phase 
protein in dogs as in horses.23 It was reported that dogs 
with babesiosis have increased blood PCT concentra-
tions,24 but that study used an assay that does not reliably 
detect canine PCT, because the assay standard does not 
actually contain PCT protein.25
Recently, an alternative commercial PCT ELISA assay 
has become available. The aims of the present study were 
therefore (i) to confirm the identity of a recombinant 
PCT protein and the assay’s protein standard using mass 
spectrometry (MS); (ii) to confirm that the assay detects 
canine PCT; (iii) to use the assay to measure canine PCT 
in plasma samples collected from dogs with sepsis and 
gastric dilatation volvulus (GDV) syndrome. The authors 
hypothesised that dogs with GDV syndrome and with 
sepsis have greater plasma PCT concentrations than 
healthy dogs and that dogs with sepsis have greater PCT 
concentrations than dogs with GDV syndrome.
MaterIals and Methods
Mass spectrometry protein identification
Purified, recombinant canine PCT (produced in Escher-
ichia coli) was purchased from a commercial source 
(ab188456, Abcam, Cambridge, Massachusetts, USA). 
This protein, and the protein standard from the commer-
cial ELISA kit were submitted to the institution’s core 
facility for protein identification by MS. Samples were 
prepared individually for protein digestion, peptide 
labelling and identification. The estimated protein mass 
in each sample was 5 µg. Proteins were solubilised with 
6 M guanidine hydrochloride and 50 mM tris (both 
Fisher Chemical, Waltham, Massachusetts, USA) and 
reduced with 110 mM dithiothreitol (Roche, Basel, Swit-
zerland), gently vortexed, centrifuged and incubated 
at 60°C for one hour. Samples were then alkylated with 
50 mM iodoacetamide (Acros Organics, Geel, Belgium), 
incubated for 30 minutes in the dark at room tempera-
ture and then quenched with additional 0.5 M dithio-
threitol. The solutions were then diluted with 50 mM 
ammonium bicarbonate (Fisher Chemical) and digested 
with 0.2 µg/µl trypsin for 18 hours at 37°C. The reaction 
was then quenched by addition of 100 per cent formic 
acid (Fisher Chemical) and samples dried in a speed 
vacuum centrifuge. The samples were then desalted 
using SOLA HRP solid-phase extraction cartridges 
(60109–003, Thermo Fisher Scientific, San Jose, Cali-
fornia, USA) preconditioned with 90 per cent methanol 
(Fisher Chemical) and 0.1 per cent trifluoroacetic acid 
(Fluka, St. Louis, Missouri, USA), eluted with 50 per cent 
acetonitrile (ACN). To remove possible detergent 
contamination, samples were run through Oasis MCX 
mixed-mode polymeric sorbent cartridges (Waters 
Corporation, Milford, Massachusetts, USA) or cation 
exchange cartridgesi preconditioned with 100 per cent 
methanol and 10 mM hydrochloric acid (Fisher Chem-
ical), washed with 95 per cent acetonitrile, 5 mM HCl 
and eluted with 10 per cent ammonium hydroxide, 
75 per cent ACN. The liquid chromatography tandem 
MS analyses were conducted using a UltiMate3000 
nanoLC device (Dionex, Sunnyvale, California, USA) 
coupled to an Orbitrap Fusion tandem mass spectrom-
eter (Thermo Fisher Scientific) equipped with a nanos-
pray ion source. Samples were reconstituted in 2 per cent 
acetonitrile and 0.5 per cent formic acid and loaded onto 
an Acclaim PepMap 100 C18 trap column (Thermo Fisher 
Scientific) for desalting followed by peptide separation 
using an Acclaim PepMap C18 nano column (75 µm x 
25 cm, Thermo Fisher Scientific).
The orbitrap mass spectrometer was operated in posi-
tive ion mode with nanospray voltage set at 1.5 kV and 
source temperature at 275°C. The orbitrap full MS survey 
scan (m/z 375–1575) was followed by top three-second 
data-dependent collision-induced dissociation MS/MS 
scans for precursor peptides with two to seven charges 
above a threshold ion count of 5000 with normalised 
collision energy of 30 per cent. MS survey scans were 
acquired at a resolving power of 120 000 (m/z 200), with 
automatic gain control (AGC) 4e5 and maximum injec-
tion time (IT) 50 ms. Tandem MS scans were acquired 
with AGC 1e4, max IT 70 ms and with isolation window 
(m/z) at 1.6 for the mass range m/z 110–2000. Dynamic 
exclusion parameters were set at 1 within 40 seconds 
exclusion duration with ±10 ppm exclusion mass width. 
All data were acquired using proprietary software (Xcal-
ibur 2.0 operation software, Orbitrap Fusion Tune Appli-
cation V.2.0, Thermo Fisher Scientific). All MS and 
MS/MS raw spectra from each sample were searched 
using proprietary software (Proteome Discoverer V.1.4, 
Thermo Fisher Scientific) and an online protein data-
base (http://www. uniprot. org/) for E coli containing 
4274 sequences, including targeted proteins. The peptide 
search was performed using a proprietary algorithm 
(Sequest HT Proteome Discoverer V.1.4), allowing two 
missed cleavage for full trypsin digestion, fixed carbami-
domethyl modification of cysteine and variable oxidation 
of methionine and deamidation of asparagine/glutamine 
residues. The peptide mass tolerance and fragment mass 
tolerance values were 10 ppm and 0.6 Da, respectively. 
Identified peptides were filtered for maximum 1 per cent 
false discovery rate and minimum peptide confidence set 
to high. Results of the search were exported by the soft-
ware as a spreadsheet.
elIsa kit protocol
PCT concentrations in all patient and control samples 
were measured in duplicate and the mean value used for 
subsequent analyses. No samples were reanalysed due to 
high coefficients of variation (CV) values. The canine 
PCT ELISA kit (Biovendor, Asheville, North Carolina, 
USA) was used per the manufacturer’s instructions with 
slight modifications. The manufacturer recommends 
diluting samples fivefold before measurement. This was 
attempted initially but the resulting absorbance values for 
control dogs were commonly below the readable range of 
the assay (data not shown). All subsequent assays were 
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performed using undiluted samples. The manufacturer 
recommends use of an automatic plate washer, but this 
apparatus was not available and hence manual washing 
was performed using 275 µl per well (instead of the 
recommended 350 µl), with the addition of a fourth wash 
at each wash step. All assays were read using a Synergy 
H1 Hybrid Multi-Mode microplate reader (Bio-Tek, 
Winooski, Vermont, USA), set per the kit manufactur-
er’s instructions and the data analysed using proprietary 
software (Gen5 Microplate Reader and Imager Software, 
Bio-Tek). Standard curves were constructed by duplicate 
measurement of the supplied protein standard, diluted 
to concentrations 12.5, 25, 50, 100, 200, 400 and 800 pg/
ml, per the manufacturer’s recommendations. Standard 
curves were generated by fitting a 4-parameter model 
(Y=(A−D)/(1+(X/C)B)+D) using an iterative series of 
calculations using the Newton-Raphson algorithm to 
determine the best curve-fit by the least squares method. 
All standard curves were manually inspected to ensure 
that the curve-fitting model consistently had R2 values of 
1.
Positive control testing
The ability of the kit to positively identify PCT was 
first tested using a recombinant canine PCT protein 
(ab188456, Abcam). This protein was reconstituted 
according to the supplier’s instructions and a dilution 
series (6.25–8000 pg/ml) constructed in PBS.
elIsa kit imprecision and lower limit of detection
To assess imprecision, samples of the kit dilution buffer 
spiked to three known final concentrations of PCT (50, 
200 and 400 pg/ml) were generated using the kit manu-
facturer’s supplied PCT protein standard. These samples 
were each then repeatedly analysed (n=20) and the mean, 
sd and CV calculated. The lower limit of the blank (LoB) 
was established as the mean blank value +1.645 x sdblank 
per Armbruster and Pry.26 The mean blank value was 
estimated by repeated measurement (n=20) of the blank 
(assay kit sample buffer). The lower limit of detection 
(LoD) was established as LoB+1.645 x sdlow conc. Data from 
repeated measurement of the low concentration sample 
in the spike/recovery experiments were used to provide 
the low concentration sd value.
Canine plasma sample analysis
Canine plasma samples were collected from patients 
managed at the two participating locations (Cornell 
University, Ithaca, New York, USA and University of 
Bologna, Italy). Specifically, stored citrate plasma samples 
collected from 30 dogs with GDV syndrome (Cornell 
n=20, Bologna n=12), and 20 dogs with sepsis (Cornell 
n=20) enrolled as part of other studies were analysed. 
After centrifugation and separation, samples were 
frozen at −80°C until the time of analysis. The longest 
duration of storage before analysis was 18 months. All 
dogs were sampled at the time of presentation to the 
recruiting institutions. Those studies were approved by 
the local Institutional Animal Care and Use Committee 
(IACUC) and undertaken with written informed client 
consent (Cornell IACUC 2014–0053; Bologna DL 
26/2014, Project 581). The diagnosis of bacterial sepsis 
was based on the 2001 Society of Critical Care Medicine 
consensus definition for sepsis27 and used established 
canine SIRS criteria,28 combined with the presence 
of highly suspected or confirmed bacterial infection. 
Specifically, the SIRS criteria employed were as follows: 
rectal temperature less than 38°C or greater than 39°C; 
heart rate greater than 120 bpm; respiratory rate greater 
than 20 rpm; total leucocyte count less than 6×109/L or 
greater than 16×109/L, or the presence of more than 3 
per cent band neutrophils.28 Dogs with bodyweight less 
than 3 kg, prolonged clotting times above the reference 
intervals or thrombocytopenia less than 30×109/L were 
excluded. The diagnosis of GDV syndrome was based on 
compatible clinical signs and the presence of character-
istic gas distension and displacement of the stomach on 
right lateral abdominal radiographs.29 Fifty-two healthy 
privately owned dogs weighing greater than 3 kg were 
enrolled as controls (Cornell n=40, Bologna n=12), again 
with local IACUC approval (Cornell IACUC 2014–0052; 
Bologna DL 26/2014, Project 581). Control dogs were 
eligible for inclusion if they had no history or evidence 
of recent or chronic medical conditions and had not 
received any medication, except for routine preventative 
healthcare, within the preceding 3 months. Dogs were 
classified healthy on the basis of history, physical exami-
nations and complete blood count and serum chemistry 
results.
statistical analysis
Before test selection, data were assessed for normality 
by assessment of histograms, calculation of skewness 
and kurtosis and with the D'Agostino Pearson test and 
descriptive statistics calculated as appropriate. Para-
metric data are presented as mean±sd, non-parametric 
data are presented as median (IQR). CVs were calculated 
as mean/sd. Procalcitonin concentrations in the healthy 
control and patient samples were not normally distrib-
uted. Thus, PCT concentrations were compared between 
dogs with sepsis, GDV syndrome and controls by Kruskal-
Wallis with Dunn’s post hoc multiple comparisons test. 
These analyses were performed using commercial soft-
ware (Prism V.7.0, GraphPad, La Jolla, California, USA). 
Alpha was set at 0.05. A reference interval (RI) for PCT 
was calculated from the healthy control data according to 
previous published recommendations.30 Briefly, healthy 
control data (n=52) were analysed for outliers by Tukey’s 
method. One outlier was identified and removed before 
RI generation using robust methods to calculate the RI 
bounds and their 90 per cent CIs. These CIs were esti-
mated by bootstrapping according to the percentile 
interval method,31 using 10 000 iterations and a random-
number seed of 928. Outlier identification and RI calcula-
tion was performed using commercial software (MedCalc 
17.8.5, MedCalc Software, Ostend, Belgium).
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results
Mass spectrometry analysis
In the sample of recombinant canine procalcitonin, 
the targeted protein was the strongest identification 
based on the protein score (online supplementary file 
1). Canine procalcitonin was identified in the ELISA kit 
assay standard, although it was not the protein with the 
strongest identification in that analysis (online supple-
mentary file 2). The strongest identification from the 
ELISA standard was for a contaminating E coli protein 
(phosphoglycerate kinase, accession P0A799). The 
protein sequence coverage, protein scores and number 
of peptide sequence matches (PSMs) were low for PCT 
in both samples (Table 1). The protein score reported by 
the MS analysis is the sum of the cross-correlation scores 
(XCorr) of individually identified peptides compared 
with the reference protein database. The PSM values for 
both proteins were low. The PSM represents the total 
number of identified peptide sequences for the protein, 
including those redundantly identified. The protein 
sequence coverage is a value calculated by dividing the 
number of amino acids in all found peptides by the total 
number of amino acids in the entire protein sequence. 
Essentially, the PSM value is a score that expresses the 
likelihood that the experimentally identified spectrum 
is derived from a specific, known protein. Hence, the 
higher the PSM value the more likely the sample contains 
the identified protein. The low PSM values, coupled with 
low sequence coverage and the low peptide XCorr values 
likely indicates an overall low abundance of PCT in the 
samples submitted for identification. The total number 
of identified proteins in both samples was low, however, 
which indicates that both samples were of good purity.
Positive control
The PCT assay kit positively identified the recombi-
nant PCT protein in a linear, concentration-dependent 
manner (R2=0.974, P<0.0001) (online supplementary file 
3), although calculated concentrations ≥400 pg/ml of 
the recombinant protein were required to generate posi-
tive test results.
Imprecision and limit of detection
CVs for the low, medium and high spike concentrations 
of the diluent buffer were 4.5, 2.7 and 1.8 per cent, 
respectively (Fig 1). A CV could not be calculated for 
the repeated measurements of the blank because all of 
the values were 0. The mean±sd value for the lower limit 
of the blank was 0 pg/ml±0. This established a value for 
the LoB of 0 pg/ml. The sd for the low concentration 
repeated measurement was 2.1. This established a value 
for the LoD of 3.4 pg/ml.
Canine plasma sample analysis
Twenty dogs with sepsis were enrolled. There were seven 
intact female dogs, six spayed female dogs, four castrated 
male dogs and three intact male dogs. The mean age was 
6.4±2.9 years. The mean bodyweight was 33.8±14.9 kg. 
All dogs met at least two/four SIRS criteria.28 The mean 
rectal temperature on presentation was 39.6±0.8°C , the 
mean heart rate was 134±32 bpm, the mean respiratory 
rate was 41±14 bpm and the median leucocyte count 
was 17.6×109/L (9.9–25.6). The causes of sepsis were 
pyometra (n=6), septic peritonitis (n=5), pneumonia 
TABLE 1: Summary data from tandem mass spectrometry identifications
Sample Accession Description Score Coverage Unique peptides PSMs
Recombinant
PCT protein
P41547 Calcitonin
Canis lupus familiaris
Gene name CALCA
4618.25 98.26 25 1520
PCT ELISA standard P41547 Calcitonin
Canis lupus familiaris
Gene name CALCA
4.00 17.39 1 1
CALCA, Calcitonin-related Polypeptide Alpha; PCT, procalcitonin; PSMs, peptide spectrum matches.
FIGURE 1: Assay repeatability and spike/recovery were 
evaluated by repeated analysis (all n=20) of samples 
spiked to known final concentrations of procalcitonin. The 
diluent buffer supplied by the manufacturer was spiked 
to three concentrations of procalcitonin (PCT) (50, 200, 
400 pg/ml) using the protein standard supplied in the kit. 
Repeated measurement (n=20) of the diluent buffer was 
used to establish the lower limit of the blank. All blank PCT 
concentrations were 0. Bars represent mean, error bars 
represent sd.
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(n=4), abscess (n=4) and osteomyelitis (n=1). Nine dogs 
had positive blood cultures. Fourteen dogs (70 per cent) 
survived to hospital discharge. All six non-survivors 
were euthanased for disease severity, development of 
life-threatening complications or perceived poor prog-
nosis. No dogs were euthanased for financial limitations.
Thirty-two dogs with GDV syndrome were enrolled. 
There were 12 castrated male dogs, 9 intact male dogs, 
8 spayed female dogs and 3 intact female dogs. The 
mean age was 8.4±3.8 years. The mean bodyweight 
was 39.1±11.5 kg. All dogs met at least two/four SIRS 
criteria.28 The mean rectal temperature on presentation 
was 38.3±1.0°C, the mean heart rate was 158±38 bpm, 
the median respiratory rate was 40 bpm (36–60) and the 
mean leucocyte count was 15.3×109/L±5.5. Twenty-four 
dogs (75 per cent) survived to hospital discharge. All eight 
non-survivors were euthanased for disease severity, devel-
opment of life-threatening complications or perceived 
poor prognosis. No dogs were euthanased for financial 
limitations. Compared with dogs with sepsis, dogs with 
GDV syndrome were significantly older (P=0.041), had 
significantly lower rectal temperatures (P<0.0001) and 
higher heart rates (P=0.016). There was no significant 
difference in bodyweight, respiratory rate or leucocyte 
counts between dogs with sepsis and those with GDV 
syndrome.
The healthy control dog population (n=52) consisted 
of 24 spayed female dogs, 12 castrated male dogs, 9 intact 
female dogs and 7 intact male dogs. The mean age was 
5.0±2.9 years. The mean bodyweight was 24.9±11.7 kg.
The calculated RI for canine PCT was 5.8–91.1 pg/ml, 
with 90 per cent CI for the lower bound of 0.0–14.3 pg/
ml and for the upper bound of 82.1–101.1 pg/ml. Using 
the whole healthy control population (n=52), the median 
PCT concentration in the dogs with sepsis 78.7 pg/ml 
(39.1–164.7) was significantly greater than in the healthy 
control dogs 49.8 pg/ml (36.2–63.7) (P=0.019). There 
was no significant difference between the median PCT 
concentrations in dogs with GDV syndrome (60.3 pg/
ml (43.3–137.2)) compared with healthy controls 
(P=0.072) or between dogs with sepsis and dogs with 
GDV syndrome (P=1.000) (Fig 2). Sample CV values were 
non-parametric. The median (IQR) CV for all samples 
was 3.4 per cent (1.8–6.7).
dIsCussIon
The present study confirmed that a commercial PCT 
ELISA detects canine PCT, has low imprecision and an 
acceptable lower LoD and demonstrates that dogs with 
sepsis have significantly increased PCT compared with 
healthy controls, but dogs with GDV syndrome do not. 
The present study aimed to confirm that the Biovendor 
canine PCT ELISA assay was able to detect canine procal-
citonin and to use it to determine plasma PCT concentra-
tions in dogs with sepsis and GDV syndrome. A previous 
publication evaluating a different commercial PCT 
ELISA25 found that the assay standard did not contain 
PCT and hence the readings from that assay could not be 
relied on. The first step in the present study was therefore 
to confirm that the Biovendor assay could identify canine 
PCT. To do this, the manufacturer’s protein standard and 
a separate recombinant canine PCT protein were tested 
for the presence of canine PCT by MS. Both the manufac-
turer’s standard and the recombinant protein contained 
pure canine PCT albeit at low concentrations.
The recombinant canine PCT protein used as a posi-
tive control was detected by the assay, confirming that 
the assay is capable of measuring canine PCT. However, 
the concentrations of protein measured with the ELISA 
were lower than the theoretical concentrations calcu-
lated per the dilution series. There are several potential 
explanations for this. First, the recombinant protein may 
have been slightly distinct from the target used to raise 
the capture antibody, perhaps not sufficient to prevent 
binding, but sufficient to reduce assay sensitivity. This 
FIGURE 2: Box and whisker plot comparison of plasma 
procalcitonin (PCT) concentrations from 40 healthy 
control dogs, 20 dogs with gastric dilatation volvulus 
(GDV) syndrome and 20 dogs with sepsis. The central 
line represents the median, the boxes represent the IQR 
and the whiskers represent the minimum and maximum 
values. Dogs with sepsis had significantly greater plasma 
concentrations of PCT compared with healthy controls 
(P=0.019) by Kruskal-Wallis with Dunn’s post hoc multiple 
comparisons test, indicated by an asterisk (*). Horizontal 
dotted lines represent the reference intervals 9.4–93.3 pg/
ml calculated by the robust method, wherein the CIs were 
estimated by bootstrapping according to the percentile 
interval method (Efron and Tibshirani), using 10 000 iterations 
and a random number seed of 928.
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may have resulted from the protein being generated in E 
coli rather than mammalian cells, since the PCT protein is 
glycosylated. Second, although the recombinant protein 
was shipped lyophilised, it is possible that some degra-
dation of the protein occurred before use or during 
reconstitution, thereby reducing the real protein concen-
tration. Third, the diluent used to generate the dilution 
series may have interfered with the assay. The protein was 
reconstituted in purified water and then diluted into PBS 
and the use of a non-protein buffer may have impacted 
the stability of the recombinant protein or impaired the 
interaction with the assay’s capture antibody. Use of the 
manufacturer supplied buffer or spiking of the recom-
binant protein into canine plasma might have provided 
a more suitable matrix and improved the correlation 
between calculated and measured concentrations.
Imprecision testing determined that the assay has low 
CVs (all CVs ≤4.5 per cent), similar to the values reported 
by the assay manufacturer (within-run CV 4.6 per cent at 
242 pg/ml, 3.7 per cent at 528.5 pg/ml). The measured 
values for the PCT concentrations in these experiments 
were all ~8 per cent lower than the expected concen-
trations. This loss of recovery was consistent across the 
concentrations and hence, it is unlikely that this would 
have a meaningful effect on comparisons between 
measurements from cases and controls. The repeated 
measurement of the blank and the low concentration 
spiked samples enabled the establishment of an LoD for 
the assay. This value is low (3.4 pg/ml), which suggests 
that the assay is capable of discriminating low concentra-
tions of PCT from background.
On the basis of human data, and from other investiga-
tions in dogs it was hypothesised that dogs with sepsis and 
dogs with GDV syndrome have increased plasma PCT 
concentrations. The results of the present study support 
the hypothesis that dogs with sepsis have increased 
plasma PCT concentrations, but suggest that dogs with 
GDV syndrome do not have increased PCT concentra-
tions relative to healthy controls. These data are some-
what consistent with the literature. Two previous studies 
have shown that mRNA for the CALCA gene is expressed 
in various tissues in dogs with sepsis and with other 
inflammatory conditions.21 22 A separate study suggested 
that blood PCT concentrations are increased in dogs 
with experimentally induced endotoxemia,32 however 
human assays may not differentiate PCT values in dogs 
with SIRS from those in healthy controls.33 Dogs with 
GDV syndrome are recognised to be commonly affected 
by SIRS,34 35 and hence were studied here to determine 
if PCT concentrations were able to distinguish non-in-
fectious SIRS from sepsis. This choice of comparative 
population is not without limitation, however, since dogs 
with GDV syndrome can develop sepsis due to bacterial 
translocation or aspiration pneumonia. These conditions 
were not identified in the GDV syndrome dogs studied, 
but could have been present subclinically. All dogs in 
the present study were sampled at the time of presen-
tation, but likely had varying durations of symptoms 
before hospital admission. Additionally, although dogs 
with GDV syndrome were studied as a population of dogs 
at-risk for SIRS, the SIRS criteria can easily be satisfied in 
dogs with GDV by tachycardia associated with shock and 
through respiratory compromise secondary to abdom-
inal distension. The data from the present study could be 
interpreted as indicating that PCT concentrations in dogs 
increase in response to pathogen interactions. However, 
the potential confounding from occult pathogen-host 
interactions in the dogs with GDV suggest that PCT may 
be acting as an acute phase reactant—responding to 
conditions associated with inflammation. Further studies 
in additional populations of dogs with sepsis and with 
other conditions causing systemic inflammation will be 
necessary to answer this question.
In human medicine, PCT measurements are discrimi-
nating for patients with infection.3 In the present study, 
there was considerable overlap in the measured PCT 
concentrations between healthy controls and the dogs 
with sepsis. Comparison with the calculated reference 
intervals also suggests that most of the patients with sepsis 
included in the present study would have been classified 
as ‘normal’. Although the present study detected a signif-
icant difference between PCT concentrations in dogs 
with sepsis compared with healthy controls, the degree 
of overlap between the measured concentrations is likely 
to substantially limit the utility of PCT measurements for 
the diagnosis of sepsis in dogs. Interestingly, there was 
considerable variation in the PCT concentrations within 
the sepsis population, with a 36-fold difference between 
the lowest and the highest measured concentration 
(absolute difference 414 pg/ml). This range suggests that 
PCT measurements might be able to distinguish subpop-
ulations of dogs with sepsis with different levels of illness 
severity. Although PCT may be of limited value for the 
diagnosis of sepsis in dogs, the authors speculate that it 
might be of value for assessment of prognosis. As such, 
further investigation of associations between PCT, illness 
severity and outcome in canine sepsis appears warranted.
In conclusion, the present study suggests that the 
canine PCT ELISA employed here can be used to measure 
plasma PCT concentrations in dogs and that dogs with 
sepsis have increased concentrations of PCT compared 
with healthy controls. Future investigations might be 
directed to confirming these findings in other sepsis 
populations, to correlating PCT with other biomarkers 
and illness severity assessments, to measuring the kinetics 
of PCT concentrations over time and to evaluating the 
prognostic value of PCT in dogs with sepsis.
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